

# Julia M W Gee

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/709644/julia-m-w-gee-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124  
papers

7,958  
citations

48  
h-index

87  
g-index

131  
ext. papers

8,578  
ext. citations

6.3  
avg, IF

5.1  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 124 | The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer.. <i>Exploration of Targeted Anti-tumor Therapy</i> , <b>2022</b> , 3, 224-239            | 2.5  |           |
| 123 | Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer.. <i>Npj Breast Cancer</i> , <b>2022</b> , 8, 57  | 7.8  | 1         |
| 122 | The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of mitosis. <i>Cellular and Molecular Life Sciences</i> , <b>2021</b> , 78, 1781-1798  | 10.3 | 12        |
| 121 | Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 320   | 17.4 | 45        |
| 120 | Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer. <i>Metallomics</i> , <b>2019</b> , 11, 1579-1592  | 4.5  | 8         |
| 119 | MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 621-632   | 8.7  | 20        |
| 118 | Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2452-2463 | 12.9 | 18        |
| 117 | Knockdown of the small conductance Ca(2+) -activated K(+) channels is potently cytotoxic in breast cancer cell lines. <i>British Journal of Pharmacology</i> , <b>2016</b> , 173, 177-90   | 8.6  | 5         |
| 116 | Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 146-59          | 7.5  | 20        |
| 115 | Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance. <i>Frontiers in Oncology</i> , <b>2016</b> , 6, 145   | 5.3  | 19        |
| 114 | Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 3269-3283  | 5.6  | 46        |
| 113 | DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. <i>Nature Communications</i> , <b>2015</b> , 6, 7758  | 17.4 | 75        |
| 112 | Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity. <i>Cell Reports</i> , <b>2015</b> , 12, 1968-77  | 10.6 | 129       |
| 111 | ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells. <i>PLoS Biology</i> , <b>2015</b> , 13, e1002330   | 9.7  | 44        |
| 110 | Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. <i>Breast Cancer Research</i> , <b>2014</b> , 16, R12  | 8.3  | 50        |
| 109 | A good drug made better: the fulvestrant dose-response story. <i>Clinical Breast Cancer</i> , <b>2014</b> , 14, 381-9  | 3    | 44        |
| 108 | Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. <i>PLoS ONE</i> , <b>2014</b> , 9, e90948                                   | 3.7  | 47        |

|     |   |     |     |
|-----|---|-----|-----|
| 107 | A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. <i>Breast Cancer Research</i> , <b>2013</b> , 15, R18            | 8.3 | 22  |
| 106 | Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. <i>FEBS Journal</i> , <b>2013</b> , 280, 5237-57  | 5.7 | 31  |
| 105 | Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , <b>2013</b> , 15, R92   | 8.3 | 248 |
| 104 | BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 1874-85   | 6.1 | 36  |
| 103 | Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 3034-41                                 | 8.7 | 12  |
| 102 | Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. <i>BMC Cancer</i> , <b>2012</b> , 12, 458   | 4.8 | 45  |
| 101 | Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e40466  | 3.7 | 44  |
| 100 | Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 133, 237-46  | 4.4 | 72  |
| 99  | A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. <i>Histopathology</i> , <b>2012</b> , 60, 854-63   | 7.3 | 18  |
| 98  | ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. <i>PLoS Biology</i> , <b>2012</b> , 10, e1001461  | 9.7 | 63  |
| 97  | Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 1488-99  | 6.1 | 101 |
| 96  | Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin $\beta$ . <i>Breast Cancer Research</i> , <b>2011</b> , 13, R29   | 8.3 | 30  |
| 95  | erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines. <i>Breast Cancer Research</i> , <b>2011</b> , 13, R93   | 8.3 | 17  |
| 94  | Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. <i>Hormone Molecular Biology and Clinical Investigation</i> , <b>2011</b> , 5, 67-73   | 7.3 | 6   |
| 93  | ONCOPOOL - a European database for 16,944 cases of breast cancer. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 56-71   | 7.5 | 74  |
| 92  | Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 119, 283-93   | 4.4 | 155 |
| 91  | Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 119, 575-91 | 4.4 | 18  |
| 90  | The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study. <i>International Journal of Cancer</i> , <b>2010</b> , 126, 1806-1816  | 7.5 | 46  |

|    |  |      |     |
|----|--|------|-----|
| 89 | Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 1550-8  | 4.6  | 56  |
| 88 | Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. <i>Journal of Pathology</i> , <b>2009</b> , 217, 32-41  | 9.4  | 48  |
| 87 | Experimental Endocrine Resistance: Concepts and Strategies <b>2009</b> , 1-26  |      |     |
| 86 | The Dark Side of Antihormonal Action in Breast Cancer <b>2009</b> , 63-84  |      | 1   |
| 85 | Adverse Features of Acquired Antihormone Resistance and Their Targeting <b>2009</b> , 139-160  |      | 1   |
| 84 | Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. <i>Breast Cancer Research</i> , <b>2008</b> , 10, R103  | 8.3  | 26  |
| 83 | Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. <i>Breast Cancer Research</i> , <b>2008</b> , 10, R26   | 8.3  | 66  |
| 82 | Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 73-83   | 7.5  | 164 |
| 81 | Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 1541-51   | 7.5  | 74  |
| 80 | Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. <i>Cancer Research</i> , <b>2008</b> , 68, 10238-46   | 10.1 | 320 |
| 79 | Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (Prestar) response and resistance. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 111, 79-91 | 4.4  | 68  |
| 78 | In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skin. <i>Pharmaceutical Research</i> , <b>2008</b> , 25, 2516-25                                  | 4.5  | 7   |
| 77 | Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. <i>Journal of Controlled Release</i> , <b>2007</b> , 117, 28-39   | 11.7 | 80  |
| 76 | Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2007</b> , 8, 241-53  | 10.5 | 44  |
| 75 | Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. <i>Journal of Clinical Pathology</i> , <b>2007</b> , 60, 1216-21  | 3.9  | 43  |
| 74 | Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4772-8   | 2.2  | 213 |
| 73 | Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 64-70  | 7.5  | 26  |
| 72 | Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. <i>Breast Cancer Research</i> , <b>2007</b> , 9, R50  | 8.3  | 40  |

|    |  |     |     |
|----|--|-----|-----|
| 71 | Endocrine resistance and breast cancer invasion. <i>Cancer Metastasis - Biology and Treatment</i> , <b>2007</b> , 137-150  |     | 1   |
| 70 | Growth factor receptor interplay and resistance in cancer. <i>Endocrine-Related Cancer</i> , <b>2006</b> , 13 Suppl 1, S45-51  | 5.7 | 59  |
| 69 | Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. <i>Endocrine-Related Cancer</i> , <b>2006</b> , 13 Suppl 1, S77-88  | 5.7 | 21  |
| 68 | Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. <i>Endocrine-Related Cancer</i> , <b>2006</b> , 13 Suppl 1, S89-97  | 5.7 | 16  |
| 67 | Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. <i>Endocrine-Related Cancer</i> , <b>2006</b> , 13, 851-61                        | 5.7 | 80  |
| 66 | Insulin-like growth factor-I receptor signaling and resistance in breast cancer. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2006</b> , 1, 33-46   | 4.1 | 3   |
| 65 | Growth factor pathway switching: implications for the use of gefitinib and trastuzumab. <i>Breast Cancer Online: BCO</i> , <b>2006</b> , 9, 1-5  |     | 2   |
| 64 | Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. <i>British Journal of Cancer</i> , <b>2006</b> , 95, 172-80  | 8.7 | 39  |
| 63 | Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 96, 131-46   | 4.4 | 115 |
| 62 | Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 97, 263-74   | 4.4 | 289 |
| 61 | Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. <i>Endocrinology</i> , <b>2005</b> , 146, 4609-18   | 4.8 | 162 |
| 60 | Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2005</b> , 93, 257-62   | 5.1 | 43  |
| 59 | Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models. <i>Breast Cancer Research</i> , <b>2005</b> , 7, 187-9   | 8.3 | 5   |
| 58 | Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. <i>Endocrine-Related Cancer</i> , <b>2005</b> , 12 Suppl 1, S85-97   | 5.7 | 35  |
| 57 | Development of strategies for the use of anti-growth factor treatments. <i>Endocrine-Related Cancer</i> , <b>2005</b> , 12 Suppl 1, S173-82  | 5.7 | 30  |
| 56 | Overview of tyrosine kinase inhibitors in clinical breast cancer. <i>Endocrine-Related Cancer</i> , <b>2005</b> , 12 Suppl 1, S135-44  | 5.7 | 74  |
| 55 | Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. <i>Endocrine-Related Cancer</i> , <b>2005</b> , 12 Suppl 1, S1-7  | 5.7 | 31  |
| 54 | Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. <i>Endocrine-Related Cancer</i> , <b>2005</b> , 12 Suppl 1, S29-36 | 5.7 | 50  |

|    |  |      |     |
|----|--|------|-----|
| 53 | Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. <i>Endocrine-Related Cancer</i> , <b>2005</b> , 12 Suppl 1, S99-S111                             | 5.7  | 160 |
| 52 | Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. <i>Endocrine-Related Cancer</i> , <b>2004</b> , 11, 793-814                                    | 5.7  | 245 |
| 51 | Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. <i>Endocrine-Related Cancer</i> , <b>2004</b> , 11, 623-41   | 5.7  | 74  |
| 50 | Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. <i>Breast Cancer Research and Treatment</i> , <b>2004</b> , 87, 167-80  | 4.4  | 109 |
| 49 | Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. <i>International Journal of Cancer</i> , <b>2004</b> , 108, 930-6  | 7.5  | 39  |
| 48 | Extreme growth factor signalling can promote oestrogen receptor-alpha loss: therapeutic implications in breast cancer. <i>Breast Cancer Research</i> , <b>2004</b> , 6, 162-3  | 8.3  | 2   |
| 47 | Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 346S-54S  | 12.9 | 91  |
| 46 | The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. <i>Endocrinology</i> , <b>2003</b> , 144, 5105-17                       | 4.8  | 147 |
| 45 | Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. <i>Endocrinology</i> , <b>2003</b> , 144, 1032-44                                    | 4.8  | 449 |
| 44 | The biology of antihormone failure in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2003</b> , 80 Suppl 1, S29-34; discussion S35  | 4.4  | 44  |
| 43 | Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. <i>Breast Cancer Research and Treatment</i> , <b>2003</b> , 81, 81-93  | 4.4  | 135 |
| 42 | ADAM metalloproteases and EGFR signalling. <i>Breast Cancer Research</i> , <b>2003</b> , 5, 223-4  | 8.3  | 28  |
| 41 | Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 110-24 | 2.2  | 405 |
| 40 | Chaperone-mediated destruction of erbB2: relevance to tyrosine kinase inhibitors. <i>Breast Cancer Research</i> , <b>2002</b> , 4, 205-6   | 8.3  | 1   |
| 39 | Clinical response and resistance to SERMs <b>2002</b> , 155-189  |      | 1   |
| 38 | The Breast Cancer Phenotype and Endocrine Response <b>2002</b> , 301-342   |      | 1   |
| 37 | Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. <i>International Journal of Cancer</i> , <b>2001</b> , 95, 247-54 | 7.5  | 196 |
| 36 | Effect of dietary GLA+/-tamoxifen on the growth, ER expression and fatty acid profile of ER positive human breast cancer xenografts. <i>International Journal of Cancer</i> , <b>2001</b> , 92, 342-7  | 7.5  | 21  |

|    |  |     |     |
|----|--|-----|-----|
| 35 | TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. <i>International Journal of Cancer</i> , <b>2001</b> , 94, 178-84                               | 7.5 | 44  |
| 34 | Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2001</b> , 65, 135-44                              | 4.4 | 31  |
| 33 | Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. <i>Endocrine-Related Cancer</i> , <b>2001</b> , 8, 175-82  | 5.7 | 105 |
| 32 | Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). <i>Endocrinology</i> , <b>2001</b> , 142, 2776-88 | 4.8 | 186 |
| 31 | Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. <i>International Journal of Cancer</i> , <b>2000</b> , 85, 643-8  | 7.5 | 69  |
| 30 | Biological and clinical associations of c-jun activation in human breast cancer. <i>International Journal of Cancer</i> , <b>2000</b> , 89, 177-86   | 7.5 | 66  |
| 29 | A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. <i>International Journal of Cancer</i> , <b>2000</b> , 89, 209-12  | 7.5 | 36  |
| 28 | Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. <i>International Journal of Cancer</i> , <b>2000</b> , 88, 363-368                                    | 7.5 | 64  |
| 27 | Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. <i>Endocrine-Related Cancer</i> , <b>1999</b> , 6, 373-87  | 5.7 | 118 |
| 26 | Endocrine response and resistance in breast cancer: a role for the transcription factor Fos. <i>International Journal of Cancer</i> , <b>1999</b> , 84, 54-61  | 7.5 | 17  |
| 25 | BRCA1 expression levels predict distant metastasis of sporadic breast cancers. <i>International Journal of Cancer</i> , <b>1999</b> , 84, 258-62   | 7.5 | 51  |
| 24 | p21(WAF1) expression and endocrine response in breast cancer. <i>Journal of Pathology</i> , <b>1999</b> , 188, 126-32  | 9.4 | 22  |
| 23 | Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. <i>Journal of Pathology</i> , <b>1999</b> , 189, 514-20                                    | 9.4 | 87  |
| 22 | The immunohistochemical expression of desmoplakin and its role in vivo in the progression and metastasis of breast cancer. <i>European Journal of Cancer</i> , <b>1999</b> , 35, 902-7                                     | 7.5 | 29  |
| 21 | c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. <i>Oncogene</i> , <b>1998</b> , 17, 1949-57   | 9.2 | 106 |
| 20 | Oestrogen-regulated genes in breast cancer: association of pLIV1 with response to endocrine therapy. <i>British Journal of Cancer</i> , <b>1998</b> , 77, 1653-6   | 8.7 | 12  |
| 19 | erbB signalling in clinical breast cancer: relationship to endocrine sensitivity. <i>Endocrine-Related Cancer</i> , <b>1997</b> , 4, 297-305   | 5.7 | 3   |
| 18 | Investigation of the mechanisms determining the inverse relationship between oestrogen and epidermal growth factor receptors in primary human breast cancer. <i>Breast</i> , <b>1997</b> , 6, 371-378                      | 3.6 | 4   |

|    |   |     |     |
|----|---|-----|-----|
| 17 | Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-alpha and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. <i>Prostate</i> , <b>1997</b> , 30, 219-31         | 4.2 | 17  |
| 16 | Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. <i>European Journal of Cancer</i> , <b>1996</b> , 32A, 413-6 | 7.5 | 43  |
| 15 | Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. <i>Breast Cancer Research and Treatment</i> , <b>1996</b> , 41, 31-41                                       | 4.4 | 37  |
| 14 | Analysis of the genes for oestrogen and epidermal growth factor receptors in human breast cancer. <i>Breast</i> , <b>1996</b> , 5, 344-350  | 3.6 | 4   |
| 13 | Mechanisms responsible for oestrogen receptor expression in primary human breast cancer. <i>Breast</i> , <b>1996</b> , 5, 237-243   | 3.6 |     |
| 12 | Properties and mode of action of pure antioestrogens in breast cancer in vitro. <i>Breast</i> , <b>1996</b> , 5, 175-180  | 3.6 | 3   |
| 11 | Growth Factors and Modulation of Endocrine Response in Breast Cancer <b>1996</b> , 225-259  |     | 2   |
| 10 | A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers. <i>Journal of Pathology</i> , <b>1995</b> , 177, 285-93  | 9.4 | 18  |
| 9  | Steroid hormone receptors and their clinical significance in cancer. <i>Journal of Clinical Pathology</i> , <b>1995</b> , 48, 890-5   | 3.9 | 21  |
| 8  | Differential expression of oestrogen regulated genes in breast cancer. <i>Acta Oncologica</i> , <b>1995</b> , 34, 641-6   | 3.2 | 32  |
| 7  | Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 761, 148-63  | 6.5 | 74  |
| 6  | Immunocytochemical localization of Fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. <i>International Journal of Cancer</i> , <b>1995</b> , 64, 269-73                                  | 7.5 | 20  |
| 5  | Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , <b>1994</b> , 29, 117-25  | 4.4 | 165 |
| 4  | Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. <i>International Journal of Cancer</i> , <b>1994</b> , 59, 619-28                                | 7.5 | 180 |
| 3  | Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , <b>1993</b> , 422, 153-9            |     | 87  |
| 2  | Estrogen deprivation in breast cancer. Clinical, experimental, and biological aspects. <i>Annals of the New York Academy of Sciences</i> , <b>1990</b> , 595, 316-27  | 6.5 | 18  |
| 1  | Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)   |     | 69  |